Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
1.200
-0.010 (-0.83%)
At close: Nov 4, 2024, 4:00 PM
1.210
+0.010 (0.83%)
Pre-market: Nov 5, 2024, 8:20 AM EST
CNTB Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CNTB stock has a target of 8.00, which predicts an increase of 566.67% from the current stock price of 1.20.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 6, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for CNTB is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +566.67% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +566.67% | Jun 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +566.67% | Apr 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +483.33% | Mar 4, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $5 | Buy | Reiterates | $5 | +316.67% | Sep 13, 2023 |
Financial Forecast
Revenue This Year
174.34M
Revenue Next Year
285.74M
from 174.34M
Increased by 63.90%
EPS This Year
-1.45
from -1.08
EPS Next Year
n/a
from -1.45
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 179.5M | 294.1M | 230.9M | ||
| Avg | 174.3M | 285.7M | 224.3M | ||
| Low | 167.5M | 274.5M | 215.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 68.7% | -19.2% | ||
| Avg | - | 63.9% | -21.5% | ||
| Low | - | 57.5% | -24.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.49 | - | -2.83 | ||
| Avg | -1.45 | - | -2.75 | ||
| Low | -1.39 | - | -2.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.